A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine.

Trial Profile

A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Telcagepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Aug 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 09 May 2009 Status changed from active, no longer recruiting to discontinued, due to elevated alanine aminotransferase levels in two patients.
    • 01 May 2009 Actual initiation date changed from Nov 2008 to Jan 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top